112 related articles for article (PubMed ID: 1300751)
21. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
22. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
Bouwhuis MG; Suciu S; Collette S; Aamdal S; Kruit WH; Bastholt L; Stierner U; Salès F; Patel P; Punt CJ; Hernberg M; Spatz A; ten Hagen TL; Hansson J; Eggermont AM;
J Natl Cancer Inst; 2009 Jun; 101(12):869-77. PubMed ID: 19509353
[TBL] [Abstract][Full Text] [Related]
23. [Effect of thymotropin on neuroendocrine regulation of the humoral immunity link in patient with neurodermatitis].
Khamidov ShA
Vestn Dermatol Venerol; 1988; (11):17-9. PubMed ID: 2853501
[No Abstract] [Full Text] [Related]
24. [The characteristics of the immunological indices in multiple myeloma during polychemotherapy].
Abdulkadyrov KM; Bessmel'tsev SS
Lik Sprava; 1995; (3-4):75-80. PubMed ID: 8819928
[TBL] [Abstract][Full Text] [Related]
25. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.
Ulloa-Montoya F; Louahed J; Dizier B; Gruselle O; Spiessens B; Lehmann FF; Suciu S; Kruit WH; Eggermont AM; Vansteenkiste J; Brichard VG
J Clin Oncol; 2013 Jul; 31(19):2388-95. PubMed ID: 23715562
[TBL] [Abstract][Full Text] [Related]
26. Melanoma vaccine momentum spurs interest, investment.
Fintor L
J Natl Cancer Inst; 2000 Aug; 92(15):1205-7. PubMed ID: 10922403
[No Abstract] [Full Text] [Related]
27. Humoral immunity in malignant skin melanoma. Isolation of melanoma specific IgG from melanoma metastases.
Kristensen E; Langvad E; Reimann R
Eur J Cancer (1965); 1976 Dec; 12(12):945-50. PubMed ID: 1009994
[No Abstract] [Full Text] [Related]
28. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma.
Kruit WH; Suciu S; Dreno B; Mortier L; Robert C; Chiarion-Sileni V; Maio M; Testori A; Dorval T; Grob JJ; Becker JC; Spatz A; Eggermont AM; Louahed J; Lehmann FF; Brichard VG; Keilholz U
J Clin Oncol; 2013 Jul; 31(19):2413-20. PubMed ID: 23715572
[TBL] [Abstract][Full Text] [Related]
29. [Some immunologic indices in patients with chronic polypous rhinosinusitis].
Iarlykov SA; Shagova VS; Iarlykov AS
Vestn Otorinolaringol; 1993; (5-6):20-2. PubMed ID: 8009764
[TBL] [Abstract][Full Text] [Related]
30. [The efficacy of taktivin in patients with viral myocarditis and dilated cardiomyopathy].
Kipshidze NN; Dzhaparidze MM; Dzidziguri LM; Rachvelishvili NB; Dateshidze MN; Demetrashvili MF
Ter Arkh; 1990; 62(9):116-8. PubMed ID: 2177920
[TBL] [Abstract][Full Text] [Related]
31. [Immunity in chronic apical periodontitis and the effect of an immunomodulator on its course].
Maksimovskiĭ IuM; Robustova TG; Mitronin AV
Stomatologiia (Mosk); 1988; 67(5):21-3. PubMed ID: 3212796
[No Abstract] [Full Text] [Related]
32. Immunologic changes in regional lymph nodes of melanoma patients.
Hammer C; Lewis MG; Rowden G; Phillips T
Chir Forum Exp Klin Forsch; 1978; (1978):235-8. PubMed ID: 313322
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of the level of humoral cytotoxins and delayed hypersensitivity skin reactions with survival of patients with melanoma of the skin].
Korosteleva TA; Vagner RI; Veresova OV; Potapenkova LS
Vopr Onkol; 1983; 29(4):38-40. PubMed ID: 6858049
[TBL] [Abstract][Full Text] [Related]
34. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of some immunological parameters in pulmonary tuberculosis].
Dubaniewicz A; Sztaba-Kania M; Hoppe A
Pol Merkur Lekarski; 2004 Feb; 16(92):123-7. PubMed ID: 15176294
[TBL] [Abstract][Full Text] [Related]
36. [Immunology and therapy of malignant melanoma (author's transl)].
Kokoschka EM; Micksche M
Wien Klin Wochenschr; 1977 Sep; 89(18):612-22. PubMed ID: 906525
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of cellular and humoral immunity and individual sensitivity of T-lymphocytes to immunocorrectors in patients with diabetic retinopathy].
Zhaboiedov HD; Bychkova NH; Skrypnik RL; Sydorova MV
Lik Sprava; 2001; (1):53-6. PubMed ID: 15311693
[TBL] [Abstract][Full Text] [Related]
38. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
[TBL] [Abstract][Full Text] [Related]
39. Cellular and humoral systemic and mucosal immune responses stimulated by an oral polybacterial immunomodulator in patients with chronic urinary tract infections.
Marinova S; Nenkov P; Markova R; Nikolaeva S; Kostadinova R; Mitov I; Vretenarska M
Int J Immunopathol Pharmacol; 2005; 18(3):457-473. PubMed ID: 16164822
[TBL] [Abstract][Full Text] [Related]
40. Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir.
Čēma I; Kleina R; Doniņa S; Isajevs S; Zablocka T; Rasa A; Alberts P
Perm J; 2022 Sep; 26(3):139-144. PubMed ID: 35950985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
